Cell and Gene Therapy Weekly News - August 28th 2025

🧬 This Week in Gene & Cell Therapy: Rocket Pharma, RMATs, CAR-T Acquisitions, and More!

From Rocket Pharma’s pivotal trial clearance to RMAT status for Stargardt disease, and the world’s first gene therapy for p47 CGD, this week’s episode delivers essential updates at the forefront of gene and cell therapy innovation. Whether you’re tracking regulatory milestones, novel AAV technologies, or the evolving landscape of in vivo CAR-T platforms—this is your go-to biotech briefing. 🔬💡

🔍 Highlights in this episode:

🚀 Rocket Pharmaceuticals’ RP-A501 trial resumes after FDA lifts clinical hold

🤝 Andelyn & Amplo partner to advance scalable NMJ gene therapies

👁️ VeonGen earns RMAT designation for Stargardt therapy targeting ABCA4

🧠 Coya Therapeutics initiates FDA-cleared Phase 2 trial for ALS

🧪 PackGene and CMRI launch barcoded AAV screening kits to accelerate discovery
🤖 Multiply Labs slashes cell therapy costs by 74% using robotic clusters

🩸 Ayrmid’s Omidubicel receives FDA Priority Review for severe aplastic anemia

🔬 jCyte shares new safety data on Retinitis Pigmentosa therapy

🧬 Kite acquires Interius in $350M deal to expand in vivo CAR-T capabilities

🇨🇦 Health Canada approves Roche’s Columvi for DLBCL

🌍 UCL and GOSH unveil the world’s first gene therapy for p47 CGD with remarkable patient recovery

This isn’t just a news roundup—it’s your weekly pulse on the scientific breakthroughs redefining the future of medicine. 🎯

📢 Stay Ahead in Gene & Cell Therapy Research!
✅ Like, share, and subscribe for weekly updates on gene and cell therapy, rare diseases, and groundbreaking biotech

#GeneTherapy #CellTherapy #BiotechNews #StargardtDisease #ALS #CAR_T #AAV #DLBCL #CGD #FDAUpdates #ClinicalTrials #BiotechInnovation #LucidQuest #LQVentures #RMAT #HealthcareConsulting #RareDiseases